Project Grant R01CA304896
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $375K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $680,507 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, San Francisco. The grant aims to elucidate mechanisms of cancer persister cell rewiring and identify druggable targets to eradicate persistence in KRAS-mutant non-small cell lung cancer. The key objectives are to: 1) illuminate signals that promote persistence in physiological contexts, 2) identify and validate targets that inhibit...
- This $607,849 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research at Weill Medical College of Cornell University to investigate mechanisms of genetic and non-genetic resistance to KRAS inhibitor drugs for the treatment of lung and colorectal cancers. The research aims to define how cancer cells can develop resistance to KRAS-targeted therapies, including through inflammatory gene expression pathways. The project will...
- This Project Grant award, valued at $411,152, was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The grant supports research at Duke University to identify and validate non-covalent interacting proteins of mutant KRAS inhibitors, which are critical for developing effective therapies for lung, pancreatic, and colorectal cancers driven by oncogenic KRAS mutations. The research aims to utilize mass spectrometry-based proteomics...
- This Project Grant award of $435,827, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate methods for enhancing the effectiveness of KRAS inhibitor cancer therapies. The research aims to identify synthetic lethal genetic interactions that could be leveraged to improve outcomes for patients with KRAS-mutated cancers, which are common in lung, colorectal, and pancreatic...
- This federal Project Grant award for $657,776.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), will support the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The University of Pittsburgh, as the awardee, will engineer the anthrax toxin protein delivery system and the DUF5 toxin effector domain to create a potent and tumor-selective RAS inactivator. This innovative approach aims to address the...
- The National Cancer Institute awarded a $269,280 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Cold Spring Harbor Laboratory, a non-profit research institution. The grant supports the development of a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The project aims to create prodrug molecules that can selectively degrade the K-RAS(G12C) protein and release cytotoxic polypharmaceuticals to concurrently target multiple pathways. The key...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- The University of Cincinnati was awarded a $162,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to support research on "Targeting the HER Family in KRAS Mutant Colorectal Cancer". The grant aims to examine novel treatment strategies combining a KRAS inhibitor with a HER3 antibody-drug conjugate containing the payload exatecan. The 2-year project, running from July 1, 2025 to June 30, 2027, will explore how colorectal cancers with KRAS...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $636,046 to the Weill Medical College of Cornell University to conduct research aimed at defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants. The key products and services to be delivered under this 5-year award, which began on November 25, 2024, include: Deciphering how cell lineage impacts the neoplastic transformation and molecular...